Table 5.

ORR and MRD based on prior treatment history

SubgroupORR*MRD-negative rate (10−5)
Patients in group, n % Patients in group, n %     
All response evaluable 82 84  11 36 
Refractory to lenalidomide 48 79 20 
Lenalidomide exposed but not refractory 30 90 50 
Refractory to bortezomib 25 84 26 
Refractory to IMiD 53 77 20 
IMiD exposed but not refractory 29 97 50 
Refractory to PI and IMiD 24 83 
Cytogenetic risk     
 High§ 13 69 67 
 Standard 52 90 33 
SubgroupORR*MRD-negative rate (10−5)
Patients in group, n % Patients in group, n %     
All response evaluable 82 84  11 36 
Refractory to lenalidomide 48 79 20 
Lenalidomide exposed but not refractory 30 90 50 
Refractory to bortezomib 25 84 26 
Refractory to IMiD 53 77 20 
IMiD exposed but not refractory 29 97 50 
Refractory to PI and IMiD 24 83 
Cytogenetic risk     
 High§ 13 69 67 
 Standard 52 90 33 
*

Data are based on a computerized algorithm.

Of the 27 patients who achieved CR or better, 11 received MRD testing.

Biomarker risk-evaluable population.

§

Includes patients who have del17p, t(14;16), t(4;14) or a combination of these by fluorescence in situ hybridization or karyotype.